Johnson & Johnson's earnings reports always seem a bit too stable when they make a move, and the target price gets raised again. The market is already numb to things like CEO share reductions. This stock is mainly about lying back and enjoying the dividends. Giants move slowly like a bull, and you get used to seeing your account barely budge. Pharmaceutical stocks, after all, stability is the most important thing, not so much fancy maneuvers.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
